November 6th, 2011 • Contributed by Dino Corvino
New research shows boys can also benefit from getting the HPV vaccine.
A government medical advisory panel said Tuesday that boys should receive the vaccination protecting them from the human papillomavirus virus.
The controversial vaccine was originally only given to girls to help prevent cervical cancer and genital warts.
Now, area health experts are offering the HPV vaccine to boys and men.
“We do have services for the Guardisil vaccination for 18 and over,” Kathy Buyeske with Family Planning Health Services said. “If they’re younger than 18, they can go to the local health department for the Guardisil vaccination.”
Research has shown more than 80 percent of anal cancer in men is related to HPV.
“The HPV vaccine is really being promoted for males ages 9-26 to help reduce their risk of contracting genital warts,” Buyeske said. “It also can protect them from penil cancer, or anal cancer also.”
The vaccine costs around $140 for each shot, but doctors say most insurance companies will cover it.
No Comments • Posted in: Cervical Cancer, Family Planning
August 2nd, 2011 • Contributed by Frances Irwin
Recently a judge placed an injunction on the Kansas law that prevents the state from including Planned Parenthood in their Medicaid provider network. So at least women won’t lose their health care while the courts review the case. More information is available here from CNN.
No Comments • Posted in: Birth Control, Cervical Cancer, Family Planning, Policy, STIs
October 24th, 2008 • Contributed by Dino Corvino
[From the National Partnership for Women and Families]
No Link Between Gardasil, Adverse Events, CDC Says
[Oct. 23, 2008]
CDC officials on Wednesday said a federal study of reported deaths and serious adverse effects in girls and women who received Merck‘s human papillomavirus vaccine Gardasil shows that the events likely are not related to the vaccine, the Wall Street Journal reports. Gardasil is designed to protect against four strains of HPV, two of which account for about 70% of cervical cancer cases, the Journal reports. The study — which is the first post-market safety study of Gardasil since the vaccine was approved in June 2006 — was based on 375,000 doses of the vaccine administered from August 2006 to July 2008 to patients ages 9 to 26. The data were collected through CDC’s Vaccine Safety Datalink program, which compiles data from several managed care organizations. Researchers compared rates of possi
Continue reading this article »
No Comments • Posted in: Cervical Cancer
January 18th, 2008 • Contributed by Frances Irwin
In this interview Nina Keck, from Vermont Public Radio, discusses the benefits of Gardasil, a vaccine that can provide protection from some cervical cancers, with public health officials.
http://www.vpr.net/news_detail/78924/
1 Comment • Posted in: Cervical Cancer
